论文部分内容阅读
[目的]评价多西他赛联合奥沙利铂治疗部分敏感复发上皮性卵巢癌的临床疗效及安全性。[方法]回顾性分析应用多西他赛联合铂类方案治疗的43例部分敏感复发上皮性卵巢癌患者的临床资料。[结果]多西他赛+奥沙利铂组(治疗组)总有效率为58.3%,1年生存率为87.5%,无进展生存时间为(7.2±2.6)个月,均略高于多西他赛+卡铂组(对照组),但无统计学意义(P>0.05)。治疗组不良反应主要为血液系统毒性,其次为消化道反应和周围神经感觉异常。治疗组血液学毒性明显低于对照组,P=0.000;两组均无Ⅲ级至Ⅳ级胃肠道反应及周围神经感觉异常。[结论]多西他赛联合奥沙利铂方案治疗部分铂类敏感复发上皮性卵巢癌疗效较好,不良反应轻,可作为部分敏感复发上皮性卵巢癌的化疗方案。
[Objective] To evaluate the clinical efficacy and safety of docetaxel and oxaliplatin in the treatment of some sensitive recurrent epithelial ovarian cancer. [Methods] The clinical data of 43 patients with partially recurrent epithelial ovarian cancer who were treated with docetaxel plus platinum regimen were retrospectively analyzed. [Results] The total effective rate of docetaxel + oxaliplatin group (treatment group) was 58.3%, the 1-year survival rate was 87.5%, the progression-free survival time was (7.2 ± 2.6) months, both slightly higher than the multi But there was no significant difference between them (P> 0.05). Adverse reactions in the treatment group were mainly hematological toxicity, followed by gastrointestinal reactions and peripheral nerve sensory abnormalities. The hematological toxicity of the treatment group was significantly lower than that of the control group, P = 0.000. There was no grade Ⅲ to Ⅳ gastrointestinal reaction and peripheral nerve sensation in both groups. [Conclusion] Docetaxel combined with oxaliplatin regimen has good curative effect on some platinum-sensitive recurrent epithelial ovarian cancer patients with mild side effects and may be used as chemotherapy regimen for some sensitive recurrent epithelial ovarian cancer.